IL6 and juvenile idiopathic arthritis: The information derived by this study will have an impact on the immediate translation of IL6 blockade in the pharmacological treatment of DMD patients, since IL6 inhibitors are already available and their use have been recently approved in children with systemic juvenile idiopathic arthritis based on a favorable benefit/risk ratio (De Benedetti et al., 2012).